ZURA

MKT CAP:$346M

Zura Bio Limited

Market Cap

$346M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$5.69+$0.14 (+2.52%)

Apr 22, 2026

Company Details

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pa...

CEO

Sandeep C. Kulkarni

IPO Date

Mar 21, 2023

Website

zurabio.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$74M

EPS (Diluted)

-$0.91

Free Cash Flow

-$48M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q4 2025

May 14, 2026

PENDING

Q3 2025

Nov 13, 2025

$0EPS -$0.21

Q2 2025

Aug 14, 2025

$0EPS -$0.17

Q1 2025

May 8, 2025

$0EPS -$0.27

FY 2024

Mar 25, 2025

$0EPS -$0.60

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 21	$0	$0	-$236.5K
Q2 21	$0	$0	-$19.1K
Q3 21	$0	$0	-$321.9K
Q4 21	$0	$0	-$514.5K
Q1 22	$0	$0	-$412.3K
Q4 22	$0	$0	-$25M
Q2 23	$0	$0	-$34M
Q3 23	$0	$0	-$10M
Q4 23	$0	$0	-$11M
Q1 24	$0	$0	-$8M
Q3 24	$0	$0	-$19M
Q1 25	$0	$0	-$19M
Q2 25	$0	$0	-$18M
Q3 25	$0	-$14.0K	-$20M

Valuation

Quarter	P/S	P/E
Q1 21	—	—
Q2 21	—	—
Q3 21	—	—
Q4 21	—	71.1x
Q1 22	—	88.8x
Q4 22	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q3 24	—	—
Q1 25	—	—
Q2 25	—	—
Q3 25	—	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q3 21	-$865.7K	-$865.7K
Q4 21	-$257.4K	-$257.4K
Q1 22	-$214.6K	-$214.6K
Q2 23	-$5M	-$11M
Q3 23	-$3M	-$5M
Q4 23	-$4M	-$4M
Q1 24	-$5M	-$10M
Q3 24	-$6M	-$6M
Q1 25	-$11M	-$11M
Q2 25	-$16M	-$16M
Q3 25	-$15M	-$15M

Capital Expenditures

Quarter	CapEx
Q3 21	$1
Q4 21	$0
Q1 22	$0
Q2 23	$6M
Q3 23	$2M
Q4 23	$0
Q1 24	$5M
Q3 24	$13.0K
Q1 25	$49.0K
Q2 25	$15.0K
Q3 25	$32.0K

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+74.4%
Q4 22	—	+129228.0%
Q2 23	—	+10434.0%
Q3 23	—	+1880.0%
Q4 23	—	+2525.8%
Q1 24	—	-66.2%
Q3 24	—	-43.0%
Q1 25	—	+89.0%
Q2 25	—	+66.8%
Q3 25	—	+133.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q3 21	$0	—
Q4 21	$0	—
Q1 22	$0	—
Q2 23	$2M	—
Q3 23	$3M	—
Q4 23	$2M	—
Q1 24	$2M	—
Q3 24	$9M	—
Q1 25	$4M	—
Q2 25	$4M	—
Q3 25	$0	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 21	—	—	$236.5K
Q2 21	—	—	$19.1K
Q3 21	—	—	$321.9K
Q4 21	—	—	$514.5K
Q1 22	—	—	$412.3K
Q4 22	$23M	$2M	—
Q2 23	$28M	$6M	—
Q3 23	$4M	$6M	—
Q4 23	$7M	$4M	—
Q1 24	$4M	$5M	—
Q3 24	$6M	$13M	—
Q1 25	$10M	$9M	—
Q2 25	$9M	$9M	—
Q3 25	$12M	$8M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$5M	$0	$5M
Q2 22	$4M	$0	$4M
Q3 22	$3M	$0	$3M
Q4 22	$2M	$0	$2M
Q1 23	$44M	$0	$44M
Q2 23	$113M	$0	$113M
Q3 23	$104M	$0	$104M
Q4 23	$100M	$0	$100M
Q1 24	$90M	$0	$90M
Q2 24	$188M	$0	$188M
Q3 24	$188M	$0	$188M
Q4 24	$176M	$0	$176M
Q1 25	$171M	$0	$171M
Q2 25	$154M	$0	$154M
Q3 25	$139M	$0	$139M
Q4 25	$109M	$0	$109M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 21	17M	—	—
Q2 21	17M	0.0%	—
Q3 21	17M	0.0%	—
Q4 21	17M	0.0%	—
Q1 22	17M	0.0%	0.0%
Q4 22	17M	0.0%	0.0%
Q2 23	34M	+98.9%	+98.9%
Q3 23	47M	+36.7%	+171.7%
Q4 23	47M	+0.4%	+172.8%
Q1 24	47M	-0.3%	+171.9%
Q3 24	87M	+86.2%	+154.6%
Q1 25	65M	-25.2%	+39.3%
Q2 25	94M	+44.4%	+100.4%
Q3 25	95M	+0.3%	+101.6%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 21	—	—
Q2 21	—	—
Q3 21	—	—
Q4 21	—	—
Q1 22	—	—
Q4 22	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q3 24	—	—
Q1 25	$0	30
Q2 25	$0	30
Q3 25	$0	30

Revenue / Employee